NCT02775292View on ClinicalTrials.gov

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1

PHASE1CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

January 3, 2017

Primary Completion Date

April 8, 2019

Study Completion Date

April 8, 2019

Conditions
Adult Solid NeoplasmChildhood Solid NeoplasmMetastatic Neoplasm
Interventions
BIOLOGICAL

Aldesleukin

Given SC

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

BIOLOGICAL

NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL

Given IV

BIOLOGICAL

NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine

Given ID

PROCEDURE

Positron Emission Tomography

Correlative studies

Trial Locations (1)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Stand Up To Cancer

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Jonsson Comprehensive Cancer Center

OTHER